BioAlliance Pharma: Livatag® Receives Fast Track Designation From The FDA For The Treatment Of Primary Liver Cancer
5/20/2014 8:43:07 AM
PARIS--(BUSINESS WIRE)--Regulatory News: BioAlliance Pharma SA (Paris:BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, today announced that Livatag® (doxorubicin Transdrug™) received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of hepatocellular carcinoma (primary liver cancer) after treatment with Sorafenib.
Help employers find you! Check out all the jobs and post your resume.
comments powered by